STRATA Skin Sciences, Inc. (SSKN)
NASDAQ: SSKN · IEX Real-Time Price · USD
3.630
+0.070 (1.97%)
At close: Jul 19, 2024, 4:00 PM
3.700
+0.070 (1.93%)
After-hours: Jul 19, 2024, 7:44 PM EDT

Company Description

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.

The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.

The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions.

It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne.

The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016.

STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

STRATA Skin Sciences, Inc.
STRATA Skin Sciences logo
Country United States
Founded 1989
IPO Date Oct 28, 2005
Industry Medical Devices
Sector Healthcare
Employees 99
CEO Dr. Dolev Rafaeli Ph.D.

Contact Details

Address:
5 Walnut Grove Drive, Suite 140
Horsham, Pennsylvania 19044
United States
Phone 215-619-3200
Website strataskinsciences.com

Stock Details

Ticker Symbol SSKN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001051514
CUSIP Number 86272A206
ISIN Number US86272A2069
Employer ID 13-3986004
SIC Code 3841

Key Executives

Name Position
Dr. Dolev Rafaeli Ph.D. President, Chief Executive Officer and Vice-Chairman
Christopher Lesovitz Chief Financial Officer
Shmuel Gov Chief Operating Officer
Jay Sturm General Counsel and Corporate Secretary
Michael E. Goodman Head of International Sales
Michael R. Stewart Independent Consultant

Latest SEC Filings

Date Type Title
Jul 18, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jul 17, 2024 8-K Current Report
Jul 11, 2024 8-K Current Report
Jun 25, 2024 8-K Current Report
Jun 24, 2024 424B5 Filing
Jun 4, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
May 15, 2024 8-K Current Report
Apr 29, 2024 10-K/A [Amend] Annual report
Apr 26, 2024 8-K Current Report